Novo Total Liab vs Cash And Short Term Investments Analysis
NVO Stock | USD 131.89 1.15 0.86% |
Novo Nordisk financial indicator trend analysis is infinitely more than just investigating Novo Nordisk AS recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Novo Nordisk AS is a good investment. Please check the relationship between Novo Nordisk Total Liab and its Cash And Short Term Investments accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.
Total Liab vs Cash And Short Term Investments
Total Liab vs Cash And Short Term Investments Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Novo Nordisk AS Total Liab account and Cash And Short Term Investments. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Novo Nordisk's Total Liab and Cash And Short Term Investments is 0.81. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Cash And Short Term Investments in the same time period over historical financial statements of Novo Nordisk AS, assuming nothing else is changed. The correlation between historical values of Novo Nordisk's Total Liab and Cash And Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Novo Nordisk AS are associated (or correlated) with its Cash And Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Short Term Investments has no effect on the direction of Total Liab i.e., Novo Nordisk's Total Liab and Cash And Short Term Investments go up and down completely randomly.
Correlation Coefficient | 0.81 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Cash And Short Term Investments
Short Term Investments is an account in the current assets section of Novo Nordisk AS balance sheet. This account contains Novo Nordisk investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Novo Nordisk AS fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.Most indicators from Novo Nordisk's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Novo Nordisk AS current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. At this time, Novo Nordisk's Selling General Administrative is very stable compared to the past year. As of the 18th of May 2024, Sales General And Administrative To Revenue is likely to grow to 0.04, while Tax Provision is likely to drop about 12.8 B.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 117.1B | 148.5B | 196.5B | 206.3B | Total Revenue | 140.8B | 177.0B | 232.3B | 243.9B |
Novo Nordisk fundamental ratios Correlations
Click cells to compare fundamentals
Novo Nordisk Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Novo Nordisk fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 125.6B | 144.9B | 194.5B | 241.3B | 314.5B | 330.2B | |
Short Long Term Debt Total | 4.5B | 10.4B | 26.6B | 25.8B | 27.0B | 28.4B | |
Other Current Liab | 15.8B | 18.4B | 21.8B | 103.9B | 30.0B | 31.5B | |
Total Current Liabilities | 59.0B | 70.3B | 99.5B | 120.9B | 169.7B | 178.1B | |
Total Stockholder Equity | 57.6B | 63.3B | 70.7B | 83.5B | 106.6B | 111.9B | |
Property Plant And Equipment Net | 50.6B | 50.3B | 55.4B | 66.7B | 91.0B | 95.5B | |
Net Debt | (11.0B) | (2.4B) | 15.9B | 13.1B | 12.6B | 13.2B | |
Retained Earnings | 57.8B | 63.8B | 72.0B | 80.6B | 104.8B | 110.1B | |
Cash | 15.5B | 12.8B | 10.7B | 12.7B | 14.4B | 8.1B | |
Non Current Assets Total | 63.2B | 79.1B | 108.9B | 133.1B | 174.8B | 183.6B | |
Non Currrent Assets Other | 841M | 674M | 267M | 206M | 1.4B | 1.4B | |
Cash And Short Term Investments | 15.5B | 12.8B | 17.5B | 23.6B | 30.2B | 31.7B | |
Net Receivables | 29.2B | 32.2B | 46.8B | 57.5B | 75.3B | 79.0B | |
Common Stock Shares Outstanding | 4.8B | 4.7B | 4.6B | 4.5B | 4.5B | 3.7B | |
Liabilities And Stockholders Equity | 125.6B | 144.9B | 194.5B | 241.3B | 314.5B | 330.2B | |
Non Current Liabilities Total | 9.0B | 11.3B | 24.2B | 36.8B | 38.3B | 40.2B | |
Inventory | 17.6B | 18.5B | 19.6B | 24.4B | 31.8B | 33.4B | |
Total Liab | 68.0B | 81.6B | 123.8B | 157.8B | 207.9B | 218.3B | |
Property Plant And Equipment Gross | 30.3B | 50.3B | 95.9B | 111.4B | 138.6B | 145.5B | |
Total Current Assets | 62.5B | 65.8B | 85.6B | 108.2B | 139.6B | 146.6B | |
Accumulated Other Comprehensive Income | (694M) | (911M) | (1.7B) | 2.4B | 1.3B | 1.3B | |
Short Term Debt | 1.5B | 7.5B | 13.7B | 1.5B | 6.5B | 6.8B | |
Intangible Assets | 5.8B | 20.7B | 38.8B | 46.3B | 55.9B | 58.7B | |
Other Current Assets | 188M | 2.3B | 1.7B | 2.7B | 2.3B | 1.5B | |
Accounts Payable | 6.4B | 5.7B | 8.9B | 15.6B | 25.6B | 26.9B | |
Common Stock Total Equity | 500M | 490M | 480M | 470M | 423M | 493.1M | |
Common Stock | 480M | 470M | 462M | 456M | 451M | 478.4M | |
Other Liab | 6.0B | 8.4B | 11.3B | 12.5B | 14.4B | 15.1B | |
Property Plant Equipment | 50.6B | 50.3B | 55.4B | 66.7B | 76.7B | 80.5B | |
Current Deferred Revenue | 35.3B | 38.7B | 55.2B | 107.6B | 123.7B | 129.9B | |
Other Assets | 5.0B | 6.5B | 8.9B | 13.4B | 15.4B | 16.2B | |
Net Tangible Assets | 51.8B | 42.7B | 27.6B | 32.1B | 36.9B | 37.0B | |
Long Term Investments | 1.8B | 1.6B | 1.4B | 1.3B | 1.7B | 1.5B | |
Short Long Term Debt | 659M | 6.7B | 12.9B | 480M | 5.3B | 2.9B | |
Long Term Debt Total | 3.0B | 2.9B | 13.0B | 24.3B | 28.0B | 29.4B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Complementary Tools for Novo Stock analysis
When running Novo Nordisk's price analysis, check to measure Novo Nordisk's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novo Nordisk is operating at the current time. Most of Novo Nordisk's value examination focuses on studying past and present price action to predict the probability of Novo Nordisk's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novo Nordisk's price. Additionally, you may evaluate how the addition of Novo Nordisk to your portfolios can decrease your overall portfolio volatility.
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |
Is Novo Nordisk's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.294 | Earnings Share 2.89 | Revenue Per Share 54.605 | Quarterly Revenue Growth 0.225 | Return On Assets 0.2524 |
The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.